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Summary 
Costimulation mediated by the CD28 molecule plays an important role in optimal activation of 
T  cells.  However,  CD28-deficient  mice can mount effective T  cell-dependent immune re- 
sponses, suggesting the existence of other costimulatory systems. In a search for other costimu- 
latory molecules on T  cells, we have developed a monoclonal antibody (mAb) that can costim- 
ulate T  cells in the absence of antigen-presenting cells (APC). The molecule recognized by this 
mAb, 9D3, was found to be expressed on almost all mature T  cells and to be a protein of ,'-~24 
kD molecular mass. By expression cloning,  this molecule was identified as CD9.  9D3  (anti- 
CD9) synergized with suboptimal doses of anti-CD3 mAb in inducing proliferation by virgin 
T  cells.  Costimulation was induced by independent ligation of CD3 and CD9, suggesting that 
colocalization of these two molecules is not required for T  cell activation. The costimulation 
by anti-CD9  was  as  potent  as  that  by anti-CD28.  Moreover,  anti-CD9  costimulated  in  a 
CD28-independent  way because anti-CD9 equally costimulated T  cells from the CD28-defi- 
cient as well as wild-type mice. Thus, these results indicate that CD9 serves as a molecule on T 
cells that can deliver a potent CD28-independent costimulatory signal. 
F 
ull  activation of the T  cell has been shown  to require 
two independent signals  (1). The first signal is provided 
by antigen-specific T  cell receptor (TCR) interacting with 
processed  antigen  peptides  plus  major  histocompatibitity 
complex (MHC) molecules on APC. This signal leads to an 
effective T  cell response only when accompanied by a sec- 
ond costimulatory signal(s) presented by the APC. The lack 
of costimulation  not  only prevents activation but also in- 
duces tolerance called anergy (1). Identifying molecules ca- 
pable of delivering costimulatory signals  has been the sub- 
ject of a large number of recent investigations (2-5). CD28 
expressed on T  cells was found to be a receptor for the co- 
stimulatory molecules CD80 and CD86 on APC (6). CD28 
engagement, by either anti-CD28 mAb or ligands (CD80/ 
CD86),  has been shown to costimulate T  cells  in the ab- 
sence  of APC,  resulting in  T  cell activation  (7-9).  Con- 
versely, the blocking of CD28-1igand interactions induced 
substantial inhibition of T  cell activation (2).  These obser- 
vations indicated  that the  CD28-CD80/CD86  interaction 
functions  as  a  critical  pathway  of T  cell  costimulation. 
Nevertheless, recent studies have revealed that CD28-defi- 
cient mice can develop normal in vivo immune responses 
(10)  and that T  cells from these mice mount APC-depen- 
dent  responses for T  cell activa~:ion  in  vitro  although  the 
response  is  reduced  compared  to  T  cells  from wild-type 
mice (10,  11). Thus, these results strongly suggest that there 
may exist other molecules capable of providing costimula- 
tory activity. 
In this report, we have developed a rat IgG mAb (9D3) 
by immunization  with  cells  of a  murine  thymic  stromal 
clone (12).  This mAb recognized a protein of"-,24 kD that 
is expressed on immunizing thymic stromal cells as well as 
murine T  cells.  By cDNA expression cloning, the antigen 
recognized by 9D3 was identified as CD9.  We found that 
9D3  (anti-CD9)  induces potent costimulation  of virgin T 
cells in the absence ofAPC. Anti-CD9 mAb almost equally 
costimulated  T  cells  from  the  CD28-deficient  as  well  as 
wild-type mice.  Thus,  these  results indicate  that  CD9  on 
murine  T  cells  delivers a  potent  costimulatory signal  that 
functions for T  cell activation in a CD28-independent way. 
Materials and Methods 
Mice.  C57BL/6 and BALB/c mice were purchased from Shi- 
zuoka Animal Laboratories (Hamamatsu, Japan).  CD28-deficient 
mice were originally generated as described (10), and a colony of 
the  CD28-deficient (CD28 -/-) mice and  wild-type (CD28 § 
control mice (13) were maintained in an animal facility at the Na- 
val Medical Research Institute. 
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rats with cells of a thymic stromal clone, MP,  LI04.8a (12).  9D3 
mAb,  anti-CD3  mAb  (145-2Cll)  (14)  and  anti-CD28  mAb 
(PV-1)  (15) were purified from ascitic fluids  of hybridomas pro- 
ducing each mAb. Control rat IgG was purchased from Biomeda 
(Foster City, CA). 
CeU Surface Biotinylation and Immunoprecipitation,  Cell surface bio- 
tinylation and immunoprecipitation were carried out as described 
(16). Briefly, cells (5 ￿  107/nil)  were suspended in saline contain- 
ing  100  mM  Hepes  (pH  8.0).  Sulfosuccinimidobiotin (Pierce 
Chemical Co.,  Rockford, ILl was  added to  cell suspension at a 
concentration  of 0.5  mg/ml.  After  a  40-min  incubation,  cells 
were  washed  and  lysed in  buffer  containing 50  mM  Tris/HC1 
(pH 7,5),  150 mM NaC1,  1% Triton X-100,  50  mM iodoaceta- 
mide,  1 mM  phenyhnethysulfonyl fluoride,  10  I.~g/ml soybean 
trypsin inhibitor, 2 mM MgC12, 2 mM CaC12, and 0.1% sodium 
azide. After a 30-rain incubation, the cell lysates were recovered 
and  incubated with  antibody-coupled Sepharose  4B  for 2  h  at 
4~  After washing with lysis buffer, bound proteins were sub- 
jected to  SDS-PAGE,  blotted onto  a  nitrocellulose membrane, 
and  visualized  with  avidin-peroxidase  (Bio-Rad  Laboratories, 
R.ichmond, CA) followed by an appropriate substrate. 
Preparation ofi  a Puttied T Cell Population.  Lymph node cells were 
depleted of B cells by imnmnomagnetic negative selection as de- 
scribed (17). Briefly, lymph node cells were incubated with Ad- 
vanced  Magnetic  Particles bound  to  goat  anti-mouse  Ig  (Ad- 
vanced  Magnetic,  Cambridge,  MA).  Surface  Ig-negative  cells 
were obtained by removing cell-bound magnetic particles with a 
rare  earth magnet  (Advanced Magnetic). This was  followed by 
complement-mediated  cytotoxic  treatment  with  anti-Ia  mAb 
(34-5-3S). Purity of the resulting population was checked by flow 
microfluorometry (FMF) with  anti-CD3.  Purified T  ceils  were 
consistently >98% CD3-positive. 
Expression Cloning qfl 9D3 An@en.  A cDNA expression library 
from FDCP-1  cells  (a myeloid cell line) was electroporated into 
Escherichia coil DH10B  and  plasmid  DNA  was  prepared  from 
pools of transformants (average  insert size ~2  kb) using Wizard 
Maxiprep resin (Promega, Madison, WI). DNA was  transfected 
into COS-I  cells (clone M6) by lipofectAMINE (GIBCO BP,  L, 
Gaithersburg,  MD)  or  DEAE-dextran  with  chloroquine  treat- 
ment as described (18). Cells in 100-ram plates were screened by 
in situ staining 48  h  after transfection. Monolayers were washed 
twice in binding buffer  (PBS,  1%  [wt/vol] bovine serum albu- 
min,  0.1%  [wt/vol]  sodium  azide),  and  then  covered in  3  ml 
binding buffer at 4~  Primary monoclonal antibody was added at 
a  final  concentration  of 2  Ixg/ml  for  I  h.  Monolayers  were 
washed three times with PBS, and then fixed with methanol for 
10 rain. After washing again in binding buffer, cells were stained 
with rabbit F(ab')2 anti-rat IgG conjugated to alkaline phospha- 
tase (Southern Biotechnology Associates, Birmingham, ALl for 1 h 
at 4~  then washed three times in binding buffer. Alkaline phos- 
phatase  activity was  visualized with  nitro  blue  tetrazolium and 
5-bromo-4-chloro-3-indolyl-phosphate (Promega, Madison, WI). 
Positive cells were scored by light microscopy. 
T Cell Cultures  for Prol!feration.  mAbs  were  immobilized  to 
wells  of  96-well  flat-bottomed  microculture  plates  (Coming 
25860,  Coming Glass Works, Coming, NY) in a final volume of 
0.1  ml.  Purified T  cells  were  cultured in  1<PM11640  medium 
supplemented with 10% fetal bovine serum and 2-mercaptoetha- 
nol at 1.5 or 2.0  ￿  105  cells/well at 5% CO2 at 37~  The cul- 
tures  were  harvested  after  an  8-h  pulse  with  20  kBq/well  of 
[3H]TdP,. Results were calculated from uptake of [3H]Tdlq, and 
expressed as the mean cpm +  SE of triplicate cultures. 
Results 
Characterization of the Antigen Recognized  by a Newly Estab- 
lished mAb,  9D3.  Wistar rats were immunized with cells of 
the  MRL104.8a  thymic  stromal clone  (12).  A  number  of 
hybridomas were  generated by fusing splenic B  cells from 
the  MP,  L104.8a-immunized  rats  with  SP2  cells.  One  of 
mAbs  designated  9D3  (IgG2b)  was  found  to  react  with 
thymocytes and peripheral (splenic and lymph node) T  cells 
as well as MRL104.8a  stromal cells (Fig. 1 A) and myeloid 
progenitor cell lines such as FDCP-1  (data not shown). 
We determined the sizes of the 9D3  target molecule by 
immunoprecipitation experiments  (Fig.  1  B).  MRL104.8a 
cells, B6  thymocytes and B6  splenic T  cells were  surface- 
biotinylated and lysed in  detergent-containing lysis buffer. 
The  cell lysates were  precipitated with  9D3-bound  beads, 
and bound proteins were subjected to SDS-PAGE. A  mo- 
nomeric  protein with  almost the  same  size was  imnmno- 
precipitated in three cell lysates and the  size was "o24  kD, 
although  it was  slightly decreased at  a  reduced  condition. 
Thus,  the results of Fig. 1 show that 9D3 recognizes a pro- 
tein of'--,24 kD  molecular mass which  is expressed on al- 
most  all  T  cells  as  well  as  cells  of a  thymic  stromal  cell 
clone, 
Isolation of 9D3 cDNA  Clone.  An  FDCP-I  cDNA  ex- 
pression  library  was  screened  in  transiently  transfected 
COS-1  cells using in situ staining with the 9D3 n~b.  Cells 
transfected with  one  pool  of ~11,000  clones and  stained 
with 9D3  mAb showed several hundred positive cells. No 
signal was found with the same cells stained with a rat iso- 
type control.  The  positive pool was subdivided into  pools 
Figure 1.  9D3 recognizes  ~24 kl) molecules expressed  on MRLI04.8a 
thymic stromal cells, thymocytes and mature T cells from C57BL/6 mice. 
(A)  MlkL104.8a  cells, C57BL/6  thymocytes  and  purified  peripheral 
(splenic and lymph node) T cells were stained with biotinylated 91)3 fol- 
lowed by PE-conjugated streptavidin. Dashed line was the staining with 
PE-conjugated streptavidin. (B) three types  of cells were surface-biotiny- 
lated,  detergent-extracted  and  precipitated  with  91)3-bound  beads. 
Bound proteins were subjected to SDS-PAGE under non-reduced  (NR) 
or reduced (R) conditions. 
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Figure 2.  Anti-CD9  mAb costimulates proliferation of virgin T  cells 
stimulated with suboptimal doses of anti-CD3  mAb. Purified C57BL/6 
lymph node T cells (2 ￿  10S/well) were cultured for 2 d in 96-well flat- 
bottomed microplates which had been coated with various doses ofanti- 
C1)3 mAb plus 10 ~tg/ml anti-CD9  mAb (A) or with various doses of 
anti-CD9 mAb plus 1 btg/nfl anti-CD3 mAb (B). 
of ~800  clones each for a second round of transfections. A 
single positive pool from  round  two  was  subdivided into 
pools of 96  clones each.  After three rounds,  a  single plas- 
mid clone (F20) containing a cDNA insert of"-q.2 kb was 
isolated.  Sequencing  and  analysis  of the  F20  cDNA  re- 
vealed complete identity at the nucleotide level to murine 
CD9  (19).  The  reactivity  of 9D3  to  COS-1  cells  trans- 
fected  with  F20  cDNA  was  confirmed  by  FMF  analyses 
(data not shown). 
The 9D3 (anti-CD9) mAb Provides T  Cell Costimulation in 
the Absence of APC.  CD9  is a  member  of the  transmem- 
brahe  4  superfamily  (TM4SF),  together  with  CD81  and 
CD82.  In considering that CD81  and CD82  have  the ca- 
pacity to modulate the growth of T  or B  cells (24, 25), we 
examined  the  effect  of the  CD9  costimulation  of TCR- 
stimulated T  cells in the absence of APC  (Fig. 2).  The re- 
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Figure 3.  Comparison ofT cell costimulation between anti-CD28 and 
anti-CD9.  Anti-CD3 (l ~g/ml) alone or together with either anti-CD9 
or anti-CD28 mAb (10 Ixg/ml) were co-immobilized in wells of micro- 
plates. B6 T cells (2 ￿  105/well)  were cultured for various days. 
sults  (a  representative  of five  experiments)  show  that  the 
9D3  mAb  increased the  proliferative response  of purified 
C57BL/6  T  cells when  coimmobilized with submitogenic 
doses  of anti-CD3  mAb:  the  9D3  mAb  immobilized at a 
given concentration (10 ~g/ml) activated T  cells that were 
stimulated with  suboptimal doses of anti-CD3  (Fig. 2  A), 
and anti-CD3 immobilized at a submitogenic dose (1  btg/ml) 
induced 9D3 dose-depended T  cell proliferation (Fig. 2 B). 
Anti-CD9  costimulation was  also observed using BALB/c 
purified  T  cells  (data  not  shown).  Neither  immobilized 
9D3 alone (Fig. 2) nor soluble 9D3 together with immobi- 
lized  anti-CD3  (data  not  shown)  induced  proliferation. 
Thus,  9D3 cross-linking can provide a costimulatory signal 
necessary to induce T  cell proliferation in response to sub- 
optimal anti-CD3 stimulation. 
Comparison of T Cell Costimulation Provided by Anti-CD28 
and Anti-CD9 mAbs.  We compared the costimulatory ac- 
tivity between anti-CD28 and anti-CD9  (9D3) mAbs. Pu- 
rified C57BL/6  T  cells were  cultured  for  1-3  d  in  wells 
coimmobilized with anti-CD28  or anti-CD9  (9D3)  plus a 
suboptimal  dose  of anti-CD3  mAb.  Optimal  concentra- 
tions of anti-CD28  for costimulation were predetermined 
as  5-10  ~g/ml.  The  results  of Fig.  3  (a  representative  of 
three  performed)  show  that  T  cell  proliferation by  anti- 
CD9  costimulation is inducible as early as 1 d  after cultur- 
ing, reaching a peak response after 2 d. Anti-CD28 costim- 
ulation failed to elicit proliferation on  day  1,  and induced 
higher levels of proliferation 3 d  rather than 2  d  after stim- 
ulation. The peak responses induced by anti-CD9 and anti- 
CD28 were comparable. 
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Figure  4.  Anti-CD9  can  costimulate proliferation of T  cells from 
CD28-deficient mice. Purified lymph node T cells (1.5 ￿  10S/well) from 
CD28 +/+ or CD28  /  mice  were stimulated with immobilized anti-CD3 
(0.5 ~,g/ml) alone or together with 5 Ixg/ml anti-CD9 (coilnmobilized) 
or 2 txg/ml anti-CD28 (in a soluble fore1) mAb. 
Anti-CD9-induced  Costimulation Is CD28-independent.  To 
determine  whether  signaling  through  CD9  ligation  was 
linked to CD28-mediated signaling, we examined the abil- 
ity of anti-CD9  to costimulate T  cells  from wild-type and 
CD28-deficient (CD28 -/-) mice. Purified T  cells from ei- 
ther type of mice were stimulated with submitogenic doses 
of anti-CD3  alone  or  in  the  presence  of coimmobilized 
9D3  mAb.  A  representative  of  three  experiments  per- 
formed  is  shown  in  Fig.  4.  Anti-CD9  cross-linking  en- 
hanced  the  proliferation  of the  CD28 -/  T  cells  equiva- 
lently  to  wild-type  T  cells.  Thus,  anti-CD9-mediated 
costimulatory  signals  do  not  require  the  involvement  of 
CD28 molecules and can function independently of CD28 
molecules. 
Discussion 
In the present study, we have developed a mAb capable 
of costimulating  fresh  T  cells  for potent  proliferation.  By 
expression  cloning,  the  molecule recognized by this  mAb 
(termed 9D3) was identified as CD9.  Our results obtained 
using the 9D3 mAb demonstrated that CD9 is expressed on 
most mature T  cells  and thymocytes at high and weak lev- 
els,  respectively,  in  addition  to  the  MRL104.Sa  thymic 
stromal  cells  used  as  immunizing  cells  for preparation  of 
mAbs.  Anti-CD9  costimulation  induced  T  cell  prolifera- 
tion in response  to suboptimal  anti-CD3  stimulation.  The 
costimulation  by anti-CD9  was as  potent  as  that  by anti- 
CD28  and  induced  almost  equally  in  T  cells  from wild- 
type and CD28 -/- mice. 
CD9 is a member of the recently discovered transmem- 
brane  four  superfamily  (TM4SF)  (reviewed  in  reference 
20). The TM4SF comprises a group of cell surface proteins 
such  as  CD81  (21-23),  CD82  (22,  24),  and  CD53  (25), 
which are characterized by the presence of four hydropho- 
bic  domains.  The  precise  biochemical  function  of  the 
TM4SF is unknown, although recent studies largely suggest 
a role for this superfamily in the regulation of cell develop- 
ment  (26,  27),  proliferation/activation  (26),  adhesion  (28) 
and motility (29). Our present results show that CD9, gen- 
erally as  a member  of the  TM4SF, joins a  growing list  of 
molecules responsible  for cell activation and specifically in 
the  T  cell,  delivers  a costimulatory signal essential  for cell 
activation (vide infra). 
Regarding  the  detection  of the  CD9  expression  using 
anti-human  (20)  or anti-murine  CD9 mAb (KMC8)  (29), 
earlier  studies  have  shown  that  CD9  is  not  expressed  by 
mature human B  and T  cells  (20,  26)  or slightly expressed 
by  only  subpopulations  of mature  murine  B  and  T  cells 
(29).  In  contrast,  anti-CD9  mAb  (9D3)  established  here 
strongly reacted with all mature murine T  ceils (Fig.  1) and 
mature murine B  cells  (our unpublished results).  Thus, our 
anti-CD9  mAb permitted  us  to investigate  the  functional 
role for the CD9 molecule expressed on mature T  cells. 
The important finding of this study is that a member of 
the TM4SF,  CD9, functions as a molecule that can deliver 
a costimulatory signal.  Four of the  TM4SF members have 
been suggested to couple to signal transduction  pathways. 
These  include  platelet  activation/aggregation  and  pre-B 
cell adhesion of CD9 (28), fresh T  cell mitogenic effects of 
CD53  (25),  and  anti-proliferative  effects  of CD81  (21). 
However,  there  has been no report which shows the  role 
of CD9 in T  ceil activation or proliferation,  probably due 
to  the  lack  of an  appropriate  anti-CD9  mAb.  This  study 
demonstrated  that anti-CD9  costimulation induced potent 
proliferation  by  freshly  isolated  T  cells  when  combined 
with suboptimal  doses of anti-CD3  stimulation,  providing 
the first evidence for the role of CD9 in T  cell activation. 
The  mechanisms  by  which  the  TM4SF  molecules  in- 
cluding CD9 transduce a signal are not known.  In this re- 
gard,  the  observations  showing molecular interactions  be- 
tween  TM4SF and immunoglobulin superfamily members 
may be worthwhile.  For example,  CD81  and  CD82 have 
been  shown to associate with the  inmmnoglobulin  super- 
family  molecules  CDt9  and  CD21  (23)  and  CD4/CD8 
molecules  (22)  on  B  or  T  cells.  The  B  cell  complex  of 
CD81, CD19 and CD21 is considered to play an important 
costimulatory role  in B  cell  activation  (23).  Similarly,  the 
association  of CD81  and  CD82  with  CD4  or  CD8  has 
been observed in T  cells  (22)  although the  functional sig- 
nificance  of these  interactions  is  unknown.  In  contrast  to 
CD81  and CD82,  CD9 is likely to be associated with the 
integrin family members such as ~1  in pre-B cells  (30) and 
~33 integrin in platelets (31). An interesting speculation may 
be raised  that the  TM4SF  plays a role  in anchoring signal 
transduction  complexes.  However,  it remains  to be  eluci- 
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members of the immunoglobulin supeffamily and/or inte- 
grin family and such an association is required for the man- 
ifestation of signal transduction. 
Our present results illustrate the expression of CD9 mol- 
ecules on mature T  cells as well as its role for T  cell activa- 
tion. Further studies will be required to investigate the ex- 
tracellular events leading to CD9 stimulation including the 
determination of the CD9-associated molecules and to elu- 
cidatae  CD9-mediated  signal  transduction.  Such  studies 
could  contribute  to  a  better  understanding  of differential 
roles of CD28 vs CD9 molecules in T  cell costimulation as 
well as the biological significance of CD9  molecules in T 
cell activation. 
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